N-(Acid-PEG2)-N-bis(PEG3-azide)
Code | Size | Price |
---|
TAR-T18371-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T18371-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
N-(Acid-PEG2)-N-bis(PEG3-azide) is a polyethylene glycol (PEG)-based linker. It is utilized in the synthesis of proteolysis targeting chimeras (PROTACs), a unique class of molecules designed for targeted protein degradation[1].
CAS:
2320560-35-6
Molecular Weight:
607.65
Purity:
0.98
SMILES:
[N-]=[N+]=NCCOCCOCCOCCN(C(=O)CCOCCOCCC(=O)O)CCOCCOCCOCCN=[N+]=[N-]
References
An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562